A Phase 2 interventional study of Biopsy of Bladder and Biospecimen Collection in Bladder Urothelial Carcinoma and Stage III Bladder Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Active, not recruiting at 216 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
How we know · 15 judgments · 4 readings being read again
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing cisplatin in Urinary Bladder Neoplasms — 5 open to participants now, 11 under way, 1 of them phase 3. Cisplatin · Urinary Bladder Neoplasms.
Among the 67 studies testing cisplatin in Urinary Bladder Neoplasms, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2021, is one of 35 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 58th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →5 of the 67 studies testing cisplatin in Urinary Bladder Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
AstraZeneca
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Assiut University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 44 · Phase 3 12 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 45 across the 66 interventional studies. Of the 50 that completed or were terminated, 22 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 67 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI): 10 open now, 23 under way, 3 of them phase 3. Of 42 finished, 21 (50%) have results posted.
Among the 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI), this one is the 49th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2021, is one of 31 in phase 2, reaches primary completion later than 1 of the 20 other live ones, and was the 55th registered.
National Cancer Institute (NCI)’s Urinary Bladder Neoplasms studies by the year they started, since 1994.
5 of the studies testing cisplatin in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06364904Phase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityA Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | 2027-04-15 |
| NCT02989584Memorial Sloan Kettering Cancer CenterA Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | 2026-12 |
| NCT05975307Sun Yat-sen UniversityTreating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation | 2026-12-31 |
| NCT07821177Dana-Farber Cancer InstituteBladder Preservation or Cystectomy for MIBC | 2027-09 |
| NCT07184021Assiut UniversityNeoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies testing cisplatin in Urinary Bladder Neoplasms, from their registry updates:
Among National Cancer Institute (NCI)’s 67 in Urinary Bladder Neoplasms:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with durvalumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy and radiation therapy with the addition of durvalumab may work better in helping tumors respond to treatment compared to chemotherapy and radiation therapy alone. Patients with limited regional lymph node involvement may benefit from attempt at bladder preservation, and use of immunotherapy and systemic chemotherapy.
PRIMARY OBJECTIVE:
I. To compare the clinical complete response rate (cCR) after chemoradiotherapy (chemoRT) with or without durvalumab in node-positive bladder cancer patients.
SECONDARY OBJECTIVES:
I. To compare the toxicity profile in both arms using the Common Terminology Criteria for Adverse Events (CTCAE).
II. To estimate the progression-free survival (PFS) in both arms. III. To estimate overall survival (OS) post randomization in both arms. IV. To estimate the bladder intact event free survival (BIEFS) in both arms. V. To estimate the metastasis free survival (MFS) in both arms. VI. To estimate bladder cancer specific survival in both arms. VII. To estimate the complete clinical response duration in both arms. VIII. To estimate salvage cystectomy rates in both arms.
EXPLORATORY OBJECTIVE:
I. Planned subgroup analyses for clinical outcome (clinical complete response [CR] rate post chemoRT +/- durvalumab, MFS, OS, PFS) based on stratification factors.
TRANSLATIONAL OBJECTIVE:
I. To collect and bank tumor tissue and blood specimens at pre-and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.
OUTLINE:
STEP 1 - Randomization: Patients are randomized to 1 of 2 arms.
ARM C: Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice a week (BIW) for 6 weeks; or cisplatin IV over 30-60 minutes once a week (QW) for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
ARM D: Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
STEP 2 - Registration: Patients are assigned to 1 of 2 arms.
ARM E: Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
ARM F: Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
After completion of study treatment, patients are followed up every 12 weeks for 1 year, every 6 months for year 2, and then annually for years 3-4.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Patient must have proven pure or mixed urothelial cancer of the bladder.
Node positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy. Node positivity can fall into either of the following categories and will be defined by imaging and/or :
A lymph node that is \< 1 cm on imaging with either a biopsy confirming involvement with cancer or high suspicion of cancer.
CT chest, abdomen, and pelvis obtained after completion of induction chemotherapy and within 8 weeks prior to step 1 randomization.
** NOTE: MRI can be used instead of CT per treating physician discretion.
Patients who achieve CR upon cystoscopy per urologist with no visible tumor (i.e., no need for additional TURBT), are allowed to proceed in the study as adequate resection with no residual disease in bladder.
CT chest, abdomen, and pelvis completed within 8 weeks prior to step 1 randomization.
** NOTE: MRI can be used instead of CT per treating physician discretion.
urologist within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair.
Documentation of correspondences with the study chair must be kept on file.
For patients who may need repeat TURBT if their old TURBT has fallen out of window: If urologist determine no visible tumor (i.e., no need for additional resection) upon cystoscopy, they are allowed to proceed in the study as complete resection. • Patient must not have received any previous radiation therapy to the pelvic area.
History of previously adequately treated non-muscle invasive bladder cancer (NMIBC) are eligible. Previously treated urothelial cancer or histological variant at any site outside of the urinary bladder are allowed, provided they have been Ta/T1/carcinoma in situ (CIS) and post treatment follow up imaging and endoscopic evaluation shows no evidence of disease.
All patients of must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
requiring more than 10 mg/d or equivalent of prednisone are not excluded. Patients with well- controlled hypothyroidism on thyroxine replacement will be eligible as well. Patients with known history of hypoadrenalism on maintenance will be eligible. Patients with type I diabetes mellitus will be eligible, provided their disease is well controlled. History of autoimmune related alopecia is also not an exclusion criteria.
. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction test is negative for HCV ribonucleic acid (RNA).
NOTE: Patient is permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist (registered trademark) are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily in order to minimize an overlap of adverse events).
Steroids as premedication for reactions (e.g., CT scan premedication).
Documentation of correspondences with the study chair must be kept on file.
ELIGIBILITY CRITERIA:
Patient on the chemoRT+ durvalumab (Arm C) must meet the following:
Platelets >= 70,000 mcL (must be obtained \< 28 days prior to step 2 registration).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Cystoscopy · Biological: Durvalumab · Drug: Fluorouracil · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Mitomycin · Radiation: Radiation Therapy
Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Cystoscopy · Drug: Fluorouracil · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Mitomycin · Radiation: Radiation Therapy
Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Cystoscopy · Biological: Durvalumab · Procedure: Magnetic Resonance Imaging
Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Cystoscopy · Procedure: Magnetic Resonance Imaging · Other: Patient Observation
Undergo bladder biopsy
Also known as: Bladder Biopsy
Undergo tumor tissue and blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Given IV
Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin
Undergo CT
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Undergo cystoscopy
Also known as: CS
Given IV
Also known as: Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736
Given IV
Also known as: 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757
Given IV
Also known as: dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011
Undergo MRI
Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Given IV
Also known as: Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin pyelocalyceal, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706
Undergo observation
Also known as: Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting
Undergo radiation therapy
Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
Clinical Complete Response
Clinical complete response is defined as complete response in bladder and nodes with no distant metastases.
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Treatment-related Grade 3 or Higher Adverse Event Rate
Proportion of patients with grade 3 or higher adverse events that are definitely, probably or possibly related to protocol therapies per the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Time frame: Assessed every 3 weeks while on treatment, up to 4 years
Progression-free Survival (PFS)
Progression-free survival is defined as the time from randomization to disease progression or death, whichever occurs first. Patients with evidence of progression in the bladder or lymph nodes that are unresectable, or with a presence of distant metastasis are considered as experiencing disease progression. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For response evaluation by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Duration of Complete Response
Duration of complete response is defined as the time from documentation of complete response to disease progression, death or last disease assessment. Clinical complete response is defined as complete response in bladder and nodes with no distant metastases. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For progression evaluated by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
1-year Overall Survival (OS) Rate
Overall survival is defined as the time from randomization to death or date last known alive. The method of Kaplan-Meier was used to estimate 1-year OS rate.
Time frame: Assessed at baseline, every 12 weeks for 1 year
Bladder Intact Event Free Survival (BIEFS)
BIEFS is defined as time from randomization to presence of muscle invasive bladder cancer, clinical evidence of progression of nodal involvement or development of met disease, radical cystectomy, or death due to any cause.
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Metastasis-free Survival (MFS)
MFS is defined as time from randomization to first evidence of metastatic disease or death from any cause.
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
1-year Bladder Cancer-specific Survival Rate
Bladder cancer-specific survival is the time from randomization to death from bladder cancer. Deaths due to other causes will be considered competing events and patients known to be alive will be censored at the date of last contact. The method of Kaplan-Meier was used to estimate 1-year bladder cancer-specific survival rate.
Time frame: Assessed at baseline, every 12 weeks for 1 year
Salvage Cystectomy Rate
Proportion of patients with salvage cystectomy performed
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Associations Between Clinical Outcomes and Stratification Factors
Planned subgroup analyses for clinical outcome (Clinical CR rate post chemoRT+/- durvalumab, MFS, OS, PFS) based on stratification factors.
Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
To Collect and Bank Tumor Tissue and Blood Specimens at Pre- and Post-treatment With chemoRT +/- Durvalumab to Determine Predictive or Prognostic Markers.
To collect and bank tumor tissue and blood specimens at pre- and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.
Time frame: Assessed at baseline and 16 weeks
The study was activated on August 25, 2020 and the first patient was enrolled on March 17, 2021. Due to slow accrual, the study was closed on October 2, 2023.
| Milestone | Arm C (chemoRT+Durvalumab) Then Arm E (Adjuvant Durvalumab) | Arm D (chemoRT) Then Arm F (Observation) | Not Randomized |
|---|---|---|---|
| Started | 5 | 3 | 3 |
| Completed | 5 | 3 | 0 |
| Not completed | 0 | 0 | 3 |
| Withdrew: Progressive disease | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Had surgery and needed to recover | 0 | 0 | 1 |
| Milestone | Arm C (chemoRT+Durvalumab) Then Arm E (Adjuvant Durvalumab) | Arm D (chemoRT) Then Arm F (Observation) | Not Randomized |
|---|---|---|---|
| Started | 5 | 3 | 0 |
| Completed | 5 | 2 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Arm C (chemoRT+Durvalumab) Then Arm E (Adjuvant Durvalumab) | Arm D (chemoRT) Then Arm F (Observation) | Not Randomized |
|---|---|---|---|
| Started | 5 | 2 | 0 |
| Completed | 2 | 1 | 0 |
| Not completed | 3 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 1 | 0 |
Clinical complete response is defined as complete response in bladder and nodes with no distant metastases.
| Participants | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Clinical Complete Response | 2 | 1 |
Proportion of patients with grade 3 or higher adverse events that are definitely, probably or possibly related to protocol therapies per the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
| Proportion of participants | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Treatment-related Grade 3 or Higher Adverse Event Rate | 0.8 (0.34 to 0.99) | 1.0 (0.37 to 1.0) |
Progression-free survival is defined as the time from randomization to disease progression or death, whichever occurs first. Patients with evidence of progression in the bladder or lymph nodes that are unresectable, or with a presence of distant metastasis are considered as experiencing disease progression. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For response evaluation by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| month | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Progression-free Survival (PFS) | 23.2 (9.5 to NA) | 9.1 (3.5 to NA) |
Duration of complete response is defined as the time from documentation of complete response to disease progression, death or last disease assessment. Clinical complete response is defined as complete response in bladder and nodes with no distant metastases. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For progression evaluated by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| month | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Duration of Complete Response | 5.4 (5.2 to 5.6) | 5.9 (5.9 to 5.9) |
Overall survival is defined as the time from randomization to death or date last known alive. The method of Kaplan-Meier was used to estimate 1-year OS rate.
| percentage of participants | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| 1-year Overall Survival (OS) Rate | 66.7 (30 to 100) | 100 (100 to 100) |
BIEFS is defined as time from randomization to presence of muscle invasive bladder cancer, clinical evidence of progression of nodal involvement or development of met disease, radical cystectomy, or death due to any cause.
| month | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Bladder Intact Event Free Survival (BIEFS) | 22.3 (9.5 to NA) | 9.1 (3.5 to NA) |
MFS is defined as time from randomization to first evidence of metastatic disease or death from any cause.
| month | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Metastasis-free Survival (MFS) | 22.3 (9.5 to NA) | 9.1 (3.5 to NA) |
Bladder cancer-specific survival is the time from randomization to death from bladder cancer. Deaths due to other causes will be considered competing events and patients known to be alive will be censored at the date of last contact. The method of Kaplan-Meier was used to estimate 1-year bladder cancer-specific survival rate.
| percentage of participants | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| 1-year Bladder Cancer-specific Survival Rate | 66.7 (30 to 100) | 100 (100 to 100) |
Proportion of patients with salvage cystectomy performed
| Participants | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) |
|---|---|---|
| Salvage Cystectomy Rate | 0 | 0 |
Planned subgroup analyses for clinical outcome (Clinical CR rate post chemoRT+/- durvalumab, MFS, OS, PFS) based on stratification factors.
Results for this outcome have not been posted.
To collect and bank tumor tissue and blood specimens at pre- and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.
Results for this outcome have not been posted.
Collected over Assessed every 3 weeks while on treatment and for 30 days after the end of treatment, up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| Arm C (ChemoRT + Durvalumab) | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Arm D (ChemoRT) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Arm E (Adjuvant Durvalumab) | 1/5 (20%) | 1/5 (20%) | 5/5 (100%) |
| Arm F (Observation) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Induction | Arm C (ChemoRT + Durvalumab) | Arm D (ChemoRT) | Arm E (Adjuvant Durvalumab) | Arm F (Observation) |
|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/4 | 1/5 | 1/3 | 0/5 | 0/2 |
| SepsisInfections and infestations | 0/4 | 0/5 | 1/3 | 1/5 | 0/2 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/5 | 1/3 | 0/5 | 0/2 |
| Wound dehiscenceInjury, poisoning and procedural complications | 1/4 | 0/5 | 0/3 | 0/5 | 0/2 |
| HypoalbuminemiaMetabolism and nutrition disorders | 1/4 | 0/5 | 0/3 | 0/5 | 0/2 |
| Adult respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 1/4 | 0/5 | 0/3 | 0/5 | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 1/4 | 1/5 | 0/3 | 0/5 | 0/2 |
| COVIDRespiratory, thoracic and mediastinal disorders | 1/4 | 0/5 | 0/3 | 0/5 | 0/2 |
| Urinary tract infectionInfections and infestations | 0/4 | 1/5 | 0/3 | 1/5 | 0/2 |
| Event | Induction | Arm C (ChemoRT + Durvalumab) | Arm D (ChemoRT) | Arm E (Adjuvant Durvalumab) | Arm F (Observation) |
|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 3/4 | 5/5 | 3/3 | 0/5 | 0/2 |
| Lymphocyte count decreasedInvestigations | 0/4 | 4/5 | 3/3 | 0/5 | 0/2 |
| FatigueGeneral disorders | 1/4 | 4/5 | 2/3 | 0/5 | 0/2 |
| DiarrheaGastrointestinal disorders | 0/4 | 4/5 | 2/3 | 0/5 | 0/2 |
| HyponatremiaMetabolism and nutrition disorders | 2/4 | 4/5 | 2/3 | 1/5 | 0/2 |
| NauseaGastrointestinal disorders | 2/4 | 3/5 | 2/3 | 0/5 | 0/2 |
| Platelet count decreasedInvestigations | 0/4 | 2/5 | 2/3 | 0/5 | 0/2 |
| White blood cell decreasedInvestigations | 1/4 | 0/5 | 2/3 | 0/5 | 0/2 |
| HyperglycemiaMetabolism and nutrition disorders | 1/4 | 0/5 | 2/3 | 2/5 | 0/2 |
| HypoalbuminemiaMetabolism and nutrition disorders | 1/4 | 1/5 | 2/3 | 0/5 | 0/2 |
All patients enrolled are included in this analysis.
| Age, Continuous(years) | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) | Not Randomized | Total |
|---|---|---|---|---|
| Median | 64.3 (63.2 to 84) | 69.6 (69.2 to 74.6) | 80.2 (79.0 to 87.6) | 73.9 (63.2 to 87.6) |
| Sex: Female, Male(Participants) | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) | Not Randomized | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 2 | 5 |
| Male | 4 | 1 | 1 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) | Not Randomized | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 3 | 3 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy) | Step 1, Arm D (Radiation Therapy, Chemotherapy) | Not Randomized | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 3 | 3 | 11 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 216 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
Ran from Mar 2021 to primary completion in Feb 2026, 58 months.
Results were first posted in Nov 2026, 9 months after primary completion.
Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's 58 months is close to that.
Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Durvalumab · Fluorouracil · Gemcitabine · Mitomycin
National Cancer Institute (NCI) →